Anti-C Reactive Protein monoclonal antibody, clone 607DU26.6.4

Aim This study aimed to identify predictive factors of glucocorticoid (GC)-free remission in patients with polymyalgia rheumatica (PMR) treated with prednisolone (PSL). Method Among 75 PMR patients in our single-center registry, this retrospective study targeted 20 patients who achieved GC-free remission (Remission group) and 30 patients who continued treatment with PSL (PSL group) at 30 months from the initiation of PSL treatment (baseline). Results There was no significant difference between Remission and PSL groups in baseline demographics. C-reactive protein (CRP) decreased more rapidly at 1 and 3 months from baseline in the Remission group than in the PSL group (P = .013 and .046, respectively). Multivariate logistic regression analysis revealed that the normalization of CRP at 1 month was associated with the achievement of GC-free remission (odds ratio = 5.83, 95% CI = 1.28-26.51,P= .023). In addition, when CRP at 1 month was <= 0.17 mg/dL, as determined by receiver operating characteristic curve analysis, both the daily PSL dose and cumulative PSL dose were lower, and the rate of GC-free remission higher, at 30 months compared to when CRP at 1 month was > 0.17 mg/dL (P = .010, .049 and .004, respectively). Conclusion The normalization of CRP within 1 month from baseline predicted GC-free remission in PMR patients treated with PSL, and resulted in a lower cumulative PSL dose.

Posaconazole (PCZ) is effective in preventing and salvage treatment invasive fungal infections in patients with hematologic disorders. However, PCZ displays highly variable individual pharmacokinetics affecting its efficacy and safety. To investigate the correlation between PCZ concentration and efficacy and safety, the following key influencing factors were explored. A total of 285 trough plasma concentrations (C-min) of 81 Chinese patients receiving PCZ oral suspension for prophylaxis or treatment of invasive fungal infections were collected in this study. The relationships between C(min)values and clinical response and hepatotoxicity were investigated as well as the incidence of clinical response under different C(min)values of PCZ with a logistic regression model. The concentration of PCZ showed remarkable differences among patients with haematologic disorders. PCZ C(min)values of 0.76 and 1.0 mu g/mL were both associated with an over 80% probability of successful response to prophylaxis and treatment of fungal infections, respectively. No association between C(min)values and hepatotoxicity was noted (P> 0.05). Gender, albumin, and co-administration of proton pump inhibitor (PPI) were identified as independent factors influencing PCZ C(min)by multiple linear regression analysis. Furthermore, patients' C-reactive protein (CRP), albumin, and co-administration of PPI exhibited significant effects on the therapeutic window of patients receiving PCZ for prophylaxis. The plasma concentration is closely associated with therapeutic efficacy of PCZ. It is necessary to adjust the dosing regimens based on PCZ C(min)to obtain an optimal therapeutic response.